Sciences de la vie en Belgique : la réindustrialisation du secteur est une priorité! fr.planet-future.be/life-sciences/…

We are thrilled to announce that we have been selected for an oral presentation at the “Educational Days” of the SFHI, held in Strasbourg from October 9 to 11, 2024!🔗 Learn more about the event: ttps://lnkd.in/gz5SQndR

New Article Featuring Our CEO Eric Halioua Published in BioProcessing - Informa Connect Eric provides valuable insights into the driving force behind our innovative platform, the resilience required to thrive in the industry, and the transformative role of global partnerships in our success.

New Article Featuring CEO of PDC*line Pharma Published in BioProcessing - Informa Connect Interview provides valuable insights into the driving force behind our innovative platform, the resilience required to thrive in the industry, and the transformative role of global partnerships in our success.

I’m thrilled to be hosting an Executive Roundtable at WuXi AppTec #WuXiGlobalForum during #JPM2025! I’m excited to discuss about opportunities of innovative cancer vaccines ! Learn more about the event here: lnkd.in/e36tbuAt

I’m thrilled to be attending the J.P. Morgan Conference in San Francisco from Sunday to Wednesday evening. If you’re attending as well and would like to connect, feel free to reach out or meet me at the conference. Looking forward to dynamic discussions in this hub of innovation!

Tomorrow’s the day! I’m excited to be speaking at Advanced Therapies UK 2025, where industry leaders will meet for two days of insightful discussions, networking, and innovation. There’s still time to join us in London—don’t miss out. #adtherapies i.snoball.it/p/GWhk/t/5

Exciting news! Our abstract has been accepted for a poster presentation at #ELCC2025. We’re proud to share new data from our ongoing clinical development program with PDC*lung01, our therapeutic cancer vaccine NSCLC. lnkd.in/eMeKgmBn

PDC*line Pharma Unveils New Clinical Results with PDC*lung01 at the #ELCC2025 . Poster Title: Primary analysis of safety, efficacy and immunogenicity of the therapeutic cancer vaccine PDClung01 with or without pembrolizumab in NSCLC: A multicenter phase I/II study

Highlights from ELCC Day 3 Alessandra Dodi Alfredo Addeo MD Dr Amol Akhade Dr. Antonio Calles 🫁🚭 Eric Halioua Giannis Mountzios Noemi Reguart Dr. Iván R. González Jarushka Naidoo Mario Occhipinti oncodaily.com/societies/2633… #Cancer #ELCC #ELCC2025 #ELCC25 #ESMO #MedX #MedEd #LungCancer #NSCLC #OncoDaily #Oncology

🤝 Clap de fin pour le Festival #Imagésanté ! Toute l’équipe de PDC*line Pharma Pharma est ravie d’avoir une nouvelle fois soutenu cette belle initiative! 📺 Si vous avez manqué cette table ronde, vous pouvez la (re)voir ici 👉 lnkd.in/ek7GCbBe

👉 New Video following poster presentation at the European Lung Cancer Congress 2025 #ELCC2025 21P PDC*lung01 cancer vaccine. We are pleased to share a video presentation by Prof. Dr. Johan Vansteenkiste, the principal investigator of our clinical trial medimix.be/onco/?p=16201

Excited to be part of the 25th #BioEquityEurope Presenting Company Class of 2025 next week in Bruges, Belgium! This year’s theme — “Can European biotech rise to the complexity of the moment?” — couldn’t be more timely. 📅 Learn more: lnkd.in/ebxFNqDm

📢 PDC*line Pharma at #CIMT 2025! Poster presented today at the 22nd Annual Meeting of the Association for Cancer Immunotherapy. 📷 Poster title: Humoral response in NSCLC patients treated with a plasmacytoid dendritic allogeneic cell line-based cancer vaccine with or without anti-PD1

In this interview, Eric Halioua reflects on the start, success and momentum of PDC*line Pharma, a clinical-stage biotechnology company developing allogeneic cellular immunotherapies for cancer. He also shares three top tips for start-up companies on their investment and funding

-> Don’t miss this article!

📢 PDC*lung01 Phase I/II results now published in ESMO Open! authors.elsevier.com/sd/article/S20… Publication of the Phase I/II clinical study evaluating the therapeutic cancer vaccine PDC*lung01 in patients with non-small cell lung cancer in ESMO Open – the journal of the ESMO - Eur. Oncology